 |
|
|
|
| Home | About | PCSK9 | News | Commentary | Trials | Videos | Resources | Contact |
 |
|
March 18, 2017: News and views from the PCSK9 Forum Editorial Board
Move over the monoclonals: Inclisiran, the first in class PCSK9 RNA interference agent, stakes a claim
ORION 1: Day 180 data look good with no variability in LDL cholesterol lowering response.
Read the report here » |
|
 |
|
Prof Kausik Ray (School of Public Health, Imperial College, London) discusses the study.
Watch the video here » |
Debunking claims about neurocognitive effects with PCSK9 inhibition
EBBINGHAUS: No objective evidence of detrimental effects over the study; follow-up continues.
Read the report here »
More views and analysis from the PCSK9 Forum Editorial Board
See all the reports & videos from ACC here »
|
|
We are reporting in real time from ACC
Tell your colleagues to join us and receive our reports
Click here to forward this email |
|
|
|
|
For the latest updates, PCSK9 news and analysis. |
|
Hot topics, news and conference reports. |
|
For videos, interviews and webcasts from leading experts. |
|
|
|
|
|
Educational Partners
and Supporters |
 |
|
 |
|
 |
|
 |
|
 |
|
|
Copyright PCSK9 Forum 2017.
Please click here to unsubscribe from future mailings. |
|
